Akebia To Present At Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will present at the following upcoming investor conferences:

• The 18^th Annual Rodman & Renshaw Global Investment Conference on Monday, September 12, 2016 at 12:30 p.m. Eastern Time. The conference is being held at the New York Palace Hotel.
• The Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 at 11:45 a.m. Eastern Time. The conference is being held at the Grand Hyatt New York.

A live audio webcast of the presentations will be available on the company’s website at http://ir.akebia.com/events.cfm. Archived presentations will be available for 90 days.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, MA, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. Akebia’s lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia has commenced its vadadustat Phase 3 program, which includes the PRO₂TECT studies for non-dialysis patients with anemia secondary to chronic kidney disease and INNO₂VATE studies for dialysis-dependent patients. For more information, please visit our website at www.akebia.com.